OPTN vs. SCPH, VERU, CHMA, AQST, XERS, OLMA, TVTX, CMPS, HRTX, and ALT
Should you be buying OptiNose stock or one of its competitors? The main competitors of OptiNose include scPharmaceuticals (SCPH), Veru (VERU), Chiasma (CHMA), Aquestive Therapeutics (AQST), Xeris Biopharma (XERS), Olema Pharmaceuticals (OLMA), Travere Therapeutics (TVTX), COMPASS Pathways (CMPS), Heron Therapeutics (HRTX), and Altimmune (ALT). These companies are all part of the "medical" sector.
OptiNose (NASDAQ:OPTN) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends.
OptiNose received 88 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 66.24% of users gave scPharmaceuticals an outperform vote while only 63.31% of users gave OptiNose an outperform vote.
OptiNose has a net margin of -41.55% compared to scPharmaceuticals' net margin of -327.29%. OptiNose's return on equity of 0.00% beat scPharmaceuticals' return on equity.
OptiNose has higher revenue and earnings than scPharmaceuticals. OptiNose is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.
OptiNose has a beta of -0.1, suggesting that its share price is 110% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500.
OptiNose presently has a consensus price target of $3.67, suggesting a potential upside of 239.51%. scPharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 385.93%. Given scPharmaceuticals' higher possible upside, analysts clearly believe scPharmaceuticals is more favorable than OptiNose.
In the previous week, OptiNose and OptiNose both had 3 articles in the media. scPharmaceuticals' average media sentiment score of 0.85 beat OptiNose's score of 0.85 indicating that scPharmaceuticals is being referred to more favorably in the news media.
85.6% of OptiNose shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 2.7% of OptiNose shares are owned by insiders. Comparatively, 5.5% of scPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
OptiNose and scPharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get OptiNose News Delivered to You Automatically
Sign up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OPTN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
OptiNose Competitors List
Related Companies and Tools
